Drugs / PADNARSERTIB
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04281420 | Apr 2020 → Oct 2023 | non-Hodgkin lymphoma | Antengene Therapeutics Limited | Terminated | No outcome recorded |
| Phase 1 | NCT02702492 | Jun 2016 → Jan 2021 | cancer, non-Hodgkin lymphoma | Karyopharm Therapeutics Inc | Terminated | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04914845 Comparator | Aug 2021 → Jul 2025 | acute myeloid leukemia | University of Colorado, Denver | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PADNARSERTIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297467 ↗ |
| Known as | ATG-019 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04281420 ↗ |
| Known as | KPT-9274 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04914845 ↗ |
| Known as | Pak4-in-1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297467 ↗ |
| Action | Inhibit | “dual inhibitor of PAK4 and NAMPT” NCT02702492 ↗ |
| Modality | Small molecule | “KPT-9274 is a first-in-class orally bioavailable, non-competitive, small molecule” NCT04914845 ↗ |
| Route | Oral | “oral KPT-9274” NCT02702492 ↗ |
| Target | NAMPT | “dual inhibitor of PAK4 and NAMPT” NCT02702492 ↗ |
| Target | PAK4 | “dual inhibitor of PAK4 and NAMPT” NCT02702492 ↗ |